In recent years, the world has witnessed frequent outbreaks of highly pathogenic avian influenza, which has caused huge economic losses to the local poultry industry. At present, it is the transition between spring and winter, when migratory birds migrate frequently, which is a season of frequent avian diseases. The prevention and control situation of avian flu in China is also very severe.

On March 17, the "China (Guangzhou) Second Avian Influenza Prevention and Control Summit Forum", organized by Guangzhou South China Biological Medicine Co.Ltd.(hereinafter referred to as:SCBM), was successfully held at the China Guangzhou Nippon Airways Hotel!

It is reported that the conference, with the theme of "Rebirth, Breakthrough, Evolution and Rebirth", invited more than 300 guests including well-known prevention and control experts of avian flu in China, representatives of breeding enterprises and industry elites to gather together to discuss the latest epidemic status and prevention and control measures of avian flu.

Group photo of the guests

At the beginning of the conference, the organizer used the micro film "Casting Shield" as a carrier to tell the development story and brilliant achievements of Rip Biotechnology in the past 25 years with high morale and inspiration. The ambition in the film was widely resonated and recognized by the guests on the scene.

President Zhu Xiutong shared the theme report "Nirvana, Breaking the Game, Evolution and Rebirth"

Zhu Xiutong first combined the breeding benefits, industrial development characteristics and trends of the domestic poultry industry in 2023, and analyzed in detail to the guests on site the new demand changes of breeding enterprises for animal protection under the depressed breeding market and fierce competition in the animal protection industry.

In response to the current "two reductions and two increases" development trend in the animal health industry—characterized by product homogenization, low capacity utilization, and insufficient market concentration—Zhu Xiutong emphasized that RuiPu Bio will prioritize organizational restructuring, R&D innovation, marketing service optimization, supply chain integration, and international expansion in 2024. Looking ahead, the company aims to build a customer-centric, forward-thinking process-oriented organization. By leveraging its six core service pillars, RuiPu Bio is committed to continuously creating value for the livestock industry and growing alongside its clients.

Professor Liao Ming, President of Zhongkai University of Agriculture and Engineering, Guangdong Province

Based on the changes of data indicators such as the number, region, host and strain of global avian flu outbreaks in recent years, Liao Ming carried out an in-depth analysis on the latest epidemic status and trend of H5 and H7 highly pathogenic avian flu in China.

Liao Ming stated that the current phase of highly pathogenic avian influenza exhibits a "three rises and one decline" epidemic trend: increased positive isolation rates, heightened viral mutations, expanded host diversity, and reduced vaccine efficacy. Notably, in 2023, both H5N6 and H5N1 strains co-occur, with H5N1 showing significant growth and continuously escalating risks. Existing H5 strains are predominantly Clade2.3.4.4b, accompanied by Clade2.3.4.4h variants, while current vaccines demonstrate diminished effectiveness against certain strains within the Clade2.3.4.4 sublineage. Regarding H7N9, the virus has accelerated HA gene evolution and enhanced adaptability, with increased infections observed in quail and other poultry species.In view of the prevention and control of highly pathogenic avian influenza, Liao Ming put forward the concept of "co-prevention of low pathogenicity and high pathogenicity avian influenza, and simultaneous treatment of avian influenza and common mixed infectious diseases", and shared a number of feasible preventive measures with the guests.

Professor Liu Jinhua from China Agricultural University delivered a keynote report entitled "Current situation and prevention strategies of low pathogenicity avian influenza"

Liu Jinhua presented detailed insights to the audience on the prevalence and clinical characteristics of low-pathogenic avian influenza viruses including H9N2, H3Ny, H10Ny, and H6 subtypes across various poultry species, supported by monitoring data. Regarding H9N2 prevention strategies, Liu highlighted that while inactivated vaccines can reduce disease severity, they cannot prevent transmission. He emphasized that activating cellular immunity or mucosal immunity remains a crucial approach, with H5N6 virus-like vaccine (HVT) candidates showing promising potential for future development.

Liu Jinhua emphasized that in recent years, the public health risks posed by avian influenza have become increasingly prominent. The continuous emergence of new avian influenza viruses has posed serious threats to human health, highlighting the complexity and long-term nature of epidemic prevention and control in the industry. With the ongoing intensification of industrial consolidation, immunizing 18-day-old embryos at hatcheries is emerging as a new strategic direction for large-scale poultry farms.

Professor Luo Kaijian, General Manager of South China Biotechnology

Luo Kaijian began by highlighting the legacy of the poultry disease research team at South China Agricultural University's College of Veterinary Medicine, then elaborated on the founding vision and development journey of South China Biological. He subsequently emphasized the core strengths of their "Qinyuan" vaccine product, particularly its breakthrough in developing core technologies for strain construction teams.

Luo Kaijian explained that Qinyuan developed its vaccine using fully avian-derived strains as the backbone and H5N8/H7N9 subtype variants as genetic donors. Through reverse genetics techniques, the company successfully engineered new vaccine strains to ensure timely updates of viral stocks. During the presentation, Luo shared comparative trial data between Qinyuan's vaccine and competing products, visually demonstrating its clinical efficacy. The insights garnered significant attention from attendees at the event.